SI1669074T1 - Uporaba megestrol acetata za izboljšanje delovanja srca in zdravljenje srčnega popuščanja - Google Patents

Uporaba megestrol acetata za izboljšanje delovanja srca in zdravljenje srčnega popuščanja

Info

Publication number
SI1669074T1
SI1669074T1 SI200431485T SI200431485T SI1669074T1 SI 1669074 T1 SI1669074 T1 SI 1669074T1 SI 200431485 T SI200431485 T SI 200431485T SI 200431485 T SI200431485 T SI 200431485T SI 1669074 T1 SI1669074 T1 SI 1669074T1
Authority
SI
Slovenia
Prior art keywords
heart
treatment
megestrol acetate
insufficiency
improving
Prior art date
Application number
SI200431485T
Other languages
English (en)
Inventor
Stefan Anker
Original Assignee
Par Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Par Pharmaceuticals Inc filed Critical Par Pharmaceuticals Inc
Publication of SI1669074T1 publication Critical patent/SI1669074T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
SI200431485T 2004-12-01 2004-12-01 Uporaba megestrol acetata za izboljšanje delovanja srca in zdravljenje srčnega popuščanja SI1669074T1 (sl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04028474A EP1669074B1 (en) 2004-12-01 2004-12-01 Use of megestrol acetate for improving heart function and the treatment of heart insufficiency

Publications (1)

Publication Number Publication Date
SI1669074T1 true SI1669074T1 (sl) 2010-10-29

Family

ID=34927608

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200431485T SI1669074T1 (sl) 2004-12-01 2004-12-01 Uporaba megestrol acetata za izboljšanje delovanja srca in zdravljenje srčnega popuščanja

Country Status (9)

Country Link
US (3) US8383612B2 (sl)
EP (2) EP1669074B1 (sl)
AT (1) ATE469650T1 (sl)
DE (1) DE602004027515D1 (sl)
DK (1) DK1669074T3 (sl)
ES (2) ES2346755T3 (sl)
PL (1) PL1863492T3 (sl)
SI (1) SI1669074T1 (sl)
WO (1) WO2006058748A1 (sl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1830924T3 (da) 2004-12-23 2013-05-21 Csl Behring Gmbh Forebyggelse af thrombedannelse og/eller -stabilisering
WO2009071405A1 (en) * 2007-12-04 2009-06-11 Charité - Universitätsmedizin Berlin Megestrol acetate for reducing the mortality and/or improving quality of life in cancer patients
US10334873B2 (en) * 2016-06-16 2019-07-02 Altria Client Services Llc Breakable capsules and methods of forming thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4370321A (en) * 1976-09-01 1983-01-25 Mead Johnson And Company Progestational adjuvant therapy
US5144017A (en) * 1988-07-13 1992-09-01 University Of Manitoba Compounds that bind to digitalis receptor
SE9600046D0 (sv) * 1996-01-05 1996-01-05 Astra Ab New pharmaceutical formulation
JP4865990B2 (ja) * 2002-04-12 2012-02-01 エラン ファーマ インターナショナル,リミティド ナノ粒子メゲストロール製剤
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
PT1558265E (pt) * 2002-11-05 2010-03-22 Bayer Schering Pharma Ag Utilização da drospirenona para o tratamento da hipertensão

Also Published As

Publication number Publication date
ATE469650T1 (de) 2010-06-15
DK1669074T3 (da) 2010-09-27
US20130143848A1 (en) 2013-06-06
EP1863492A1 (en) 2007-12-12
US8383612B2 (en) 2013-02-26
WO2006058748A1 (en) 2006-06-08
DE602004027515D1 (de) 2010-07-15
PL1863492T3 (pl) 2013-10-31
ES2423944T3 (es) 2013-09-25
US20160101117A1 (en) 2016-04-14
EP1669074A1 (en) 2006-06-14
EP1863492B1 (en) 2013-05-08
ES2346755T3 (es) 2010-10-20
US20080139521A1 (en) 2008-06-12
EP1669074B1 (en) 2010-06-02

Similar Documents

Publication Publication Date Title
WO2006091693A3 (en) Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor
IL178151A0 (en) Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful in the treatment of type 2 diabetes
WO2006068729A3 (en) Methods and compositions for enhancing iron absorption
WO2006073890A3 (en) Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
MXPA02007639A (es) Inhibidores de la oxidacion parcial de los acidos grasos en el tratamiento de la falla cardiaca congestiva.
HK1100353A1 (en) Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
WO2007024700A8 (en) Exendin for treating diabetes and reducing body weight
PL1771192T3 (pl) Stosowanie asparaginianu do regulowania poziomów glukozy we krwi
TW200724101A (en) Medical sensor and technique for using the same
WO2007124461A8 (en) Glp-1 compounds
WO2005086860A3 (en) Methods for generating insulin-producing cells
CO6210752A2 (es) Compuestos biciclicos y uso como antidiabeticos
PA8525201A1 (es) Tetrazolil-fenil acetamidas como activadores de la glucoquinasa
HK1095762A1 (en) Ctgf as target for the therapy of microalbuminuriain patients with diabetic nephropathy
MX2007013834A (es) Terapias de enfermedades vasculares.
HK1121083A1 (en) Methods for reducing blood pressure
GB0521716D0 (en) Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
PL1863492T3 (pl) Zastosowanie octanu megestrolu dla poprawy czynności serca i leczenia niewydolności serca
IL182681A0 (en) Coadministration of tigecycline and digoxin
ATE449600T1 (de) Verwendung von glycerin zur verbesserung der herzfunktion
PT1670489E (pt) Utilização de xénon com hipotermia para o tratamento de asfixia neonatal
EP1722799A4 (en) TREATMENT OF PULMONARY ARTERIAL HYPERTENSION BY DHEA, ITS ANALOGUES OR DERIVATIVES
EP2214634A4 (en) SKIN MOISTURIZER, PROMOTER OF BLOOD CIRCULATION, AND EXTERNAL SKIN PRODUCTS CONTAINING MOISTURIZER FOR THE SKIN AND THE PROMOTER OF BLOOD CIRCULATION
ZA200705470B (en) Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level